tbuckley/cabot-search huggingface dataset:
AB1299 Functional capacity measured by haq in patients with rheumatic diseases in colombia
Authors: F.M. Cuervo, A. Santos, E.L. Saldarriaga, J.C. Rueda, I. Angarita, J. Ballesteros, I. Peláez, E. Forero, J. Ramirez, J. Londono
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Functional capacity is an important indicator of quality of life that is affected in different pathologies and is susceptible to intervention in early stages once it is recognised. In rheumatic diseases, functional limitation has a great impact that is evidenced by multiple degrees of long-term disability. <h3>Objectives</h3> To evaluate the functional capacity in different rheumatic diseases by HAQ (Health Assessment Questionnaire) instrument. <h3>Methods</h3> In the context of the prevalence study of rheumatic disease in Colombia, the assessment of functional capacity was measured by using the HAQ score, where functional limitation is scored in a range from 0 to 3 points according to the severity of limitation. The major functional limitation is scored 3 and not limitation 0. A total of 4020 individuals answered the questionnaire. <h3>Results</h3> Patients with rheumatic diseases (n=2274) reported a greater degree of limitation compared with disease-free people (n=1104) or non-rheumatic patients (n=642) (p&lt;0,001). Especially patients with rheumatoid arthritis (RA) had the worst score (0.88±0,72) compared to 0.06±0,22 and 0.01±0,14 of the population with non-rheumatic and healthy population, respectively (p&lt;0.001). The HAQ score in the remaining diseases was 0,67 (SD ±0,62) for systemic lupus erythematosus (SLE), followed by patients with osteoarthrosis (OA) 0,59 (SD ±0,58), fibromyalgia (FM) 0,56 (SD ±0,57) and spondylarthritis (SpA) 0,52 (SD ±0,43). Functional capacity evaluated by HAQ, the points represent the mean of the instrument. * RA: Rheumatoid Arthritis; SLE: Systemic Lupus Erythematosus; OA: Osteoarthritis; FM: Fibromyalgia; SpA: Spondyloarthritis; CHIKV: Chikungunya fever; RRPS: Rheumatic Regional Pain Syndromes (Rotator cuff tendinopathy, shoulder bicipital tendinopathy, lateral and medial medial epicondylalgia, Quervain's tendinopathy, carpal tunnel syndrome, Dupuytren's contracture, trochanteric syndrome, anserine bursitis, achilles tendonopathy, plantar talalgia); NEMD: non-specific musculoskeletal disease. <h3>Conclusions</h3> In comparison with disease-free population and non-rheumatic patients, the rheumatic patients had a lower functional capacity measured by HAQ. Patients with RA had more disability followed by patients with SLE and OA. <h3>Disclosure of Interest</h3> None declared
Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience
Authors: Amandeep Salhotra, Dongyun Yang, Bernard Tegtmeier, Sally Mokhtari, Justine Abella Ross, Karamjeet S Sandhu, Ibrahim Aldoss, Haris Ali, Matthew Mei, Monzr Al Malki, Akemi Meguro, James Ito, Jana Dickter, Jasmine Zain, Margaret O'Donnell, Ricardo Spielberger, David S Snyder, Auayporn P. Nademanee, Anthony S. Stein, Guido Marcucci, Stephen J Forman, Ryotaro Nakamura, Sanjeet Dadwal
Journal: Blood (2018)
AB0383 Changes of metabolic biomarker levels upon anti-tnf therapy in rheumatoid arthritis patients
Authors: N. Bodnár, A. Pusztai, E. Végh, Á. Horváth, S. Szántó, G. Szücs, A. Hamar, A. Domján, K. Hodosi, I. Seres, G. Kerekes, Z. Szekanecz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid arthritis (RA) has been associated with cardiovascular disease and metabolic syndrome. Numerous pro-inflammatory cytokines (e.g. TNF-α, IL-1, IL-6) are released, which cytokines cause increased reactive oxygen species (ROS) production and thereby contribute to the increased lipid peroxidation and reduction of many antioxidants. These processes not only lead to the deterioration of joints and other tissues but may also contribute to comorbidities, such as atherosclerosis. <h3>Objectives</h3> The aim of this study was to assess the effects of anti-TNF therapy on different metabolic markers, such as PON1 (paraoxonase 1), arylesterase, chemerin and adiponectin. We also investigated whether these biomarkers correlated with various demographic, clinical and laboratory markers. <h3>Methods</h3> We treated 37 RA patients with either etanercept (ETN) or certolizumab pegol (CZP) in a 12 month follow-up study. Assessments were performed at baseline, and 3, 6 and 12 months after treatment initiation. Serum chemerin and adiponectin concentrations were measured by commercially available ELISA kits (R and D System, MN and USA). PON1 and arylesterase activities were measured by spectrophotometry. In addition, age, disease duration, disease activity (DAS28), CRP, anti-CCP, IgM rheumatoid factor and plasma lipid levels were also assessed. Arterial flow-mediated vasodilation (FMD), carotid intima-media thickness (cIMT) and arterial pulse-wave velocity (PWV) were assessed by ultrasound. <h3>Results</h3> Anti-TNF treatment resulted in a significant decrease in the levels of chemerin (p&lt;0.001) and adiponectin (p&lt;0.007) after 12 months. There were no significant changes in the levels of other metabolic biomarkers. We found the following correlations between the baseline values: the PON1 levels correlated with the age of patients (R=0.466, p=0.004). The adiponectin correlated with the disease activity (R=0.385, p=0.030), HDL-C (R=0.417, p=0.012) and the triglyceride levels (R=0.481, p=0.003). The total cholesterol correlated with the PWV (R=0.449, p=0.021) and the levels of the LDL-C (R=0.911, p&lt;0.001). The baseline triglyceride correlated with the IgM rheumatoid factor (R=0.343, p=0.021); and the levels of LDL-C correlated with the PWV values (R=0.444, p=0.023). <h3>Conclusions</h3> Metabolic factors, such as certain adipokines, PON1 and arylesterase may play a role in oxidative stress and atherosclerosis associated with RA. Anti-TNF treatment may affect adipokine levels. <h3>Disclosure of Interest</h3> None declared
Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1
Authors: Daniel Ernst, Brent A. Williams, Xing-Hua Wang, Nara Yoon, Kyung-Phil Kim, Jodi Chiu, Zhi Juan Luo, Karin G. Hermans, Joerg Krueger, Armand Keating
Journal: Blood Cancer Journal (2019)

Abstract CD123 (IL-3Rα) is frequently expressed by malignant Hodgkin lymphoma (HL) cells. Naked monoclonal antibodies (mAb) against HL lack clinical benefit, partially due to absence of natural killer (NK) cells in the tumor microenvironment. Here we show that the combination of a fully humanized anti-CD123 mAb (CSL362) and high-affinity Fcγ-receptor NK-92 cells (haNK) effectively target and kill HL cells in vitro. First, we confirmed high expression of CD123 in 2 of the 3 HL cell lines (KM-H2 and L-428), and its absence in NK cells. Cytotoxicity of haNK cells against CD123-positive HL cells was significantly higher in the presence of CSL362. This was also shown with IL-15-activated primary NK cells, although haNK cells showed a 10.87-fold lower estimated half-maximal stimulatory effective concentration (EC 50 ). CSL362 facilitated a significant increase in the expression of CD107a, intracellular IFN-γ and TNF-α and enhanced expression of c-JUN , PLD-1 , and ARF6 by NK cells. Inhibition of the ARF6–PLD-1 axis (NAV2729), but not of the MAPK pathway (U0126), completely abrogated CSL362-facilitated antibody-dependent cell-mediated cytotoxicity (ADCC) in haNK and activated primary NK cells. Our results support CD123 as an immunotherapeutic target for HL and the combination of NK cells and CSL362 as a treatment strategy for HL.
Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
Authors: Thomas S. G. Sehested, Jenny Bjerre, Seul Ku, Andrew Chang, Alison Jahansouz, Douglas K. Owens, Mark A. Hlatky, Jeremy D. Goldhaber-Fiebert
Journal: JAMA Cardiology (2019)

In the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, the anti-inflammatory monoclonal antibody canakinumab significantly reduced the risk of recurrent cardiovascular events in patients with previous myocardial infarction (MI) and high-sensitivity C-reactive protein (hs-CRP) levels of 2 mg/L or greater.To estimate the cost-effectiveness of adding canakinumab to standard of care for the secondary prevention of major cardiovascular events over a range of potential prices.A state-transition Markov model was constructed to estimate costs and outcomes over a lifetime horizon by projecting rates of recurrent MI, coronary revascularization, infection, and lung cancer with and without canakinumab treatment. We used a US health care sector perspective, and the base case used the current US market price of canakinumab of $73 000 per year. A hypothetical cohort of patients after MI aged 61 years with an hs-CRP level of 2 mg/L or greater was constructed.Canakinumab, 150 mg, administered every 3 months plus standard of care compared with standard of care alone.Lifetime costs and quality-adjusted life-years (QALYs), discounted at 3% annually.Adding canakinumab to standard of care increased life expectancy from 11.31 to 11.36 years, QALYs from 9.37 to 9.50, and costs from $242 000 to $1 074 000, yielding an incremental cost-effectiveness ratio of $6.4 million per QALY gained. The price would have to be reduced by more than 98% (to $1150 per year or less) to meet the $100 000 per QALY willingness-to-pay threshold. These results were generally robust across alternative assumptions, eg, substantially lower health-related quality of life after recurrent cardiovascular events, lower infection rates while receiving canakinumab, and reduced all-cause mortality while receiving canakinumab. Including a potential beneficial effect of canakinumab on lung cancer incidence improved the incremental cost-effectiveness ratio to $3.5 million per QALY gained. A strategy of continuing canakinumab selectively in patients with reduction in hs-CRP levels to less than 2 mg/L would have a cost-effectiveness ratio of $819 000 per QALY gained.Canakinumab is not cost-effective at current US prices for prevention of recurrent cardiovascular events in patients with a prior MI. Substantial price reductions would be needed for canakinumab to be considered cost-effective.
SAT0340 Psa-disk, a novel visual instrument to assess the burden of disease in psoriatic arthritis patients
Authors: M.S. Chimenti, M. Esposito, M. Teoli, D. Graceffa, G. Peluso, D. Birra, G. Moretta, A. Galossi, V. Carboni, F. Sensi, A. Mazzotta, S. Urbani, E. Del Duca, N. Bernardini, R. Caccavale, P. Sessa, A. Richetta, C. De Simone, E. Gremese, C. Bonifati, K. Peris, R. Perricone, S. Persechino, D. Kostaki, M. Paroli, M.C. Potenza, G. Sebastiani, L. Bianchi, R. Scrivo, F. Ceccarelli, S. Calvieri, G. Valesini
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The assessment of joint disease in psoriasis (PsO) patients is paramount, particularly where consensus among dermatology and rheumatology specialists is necessary. <h3>Objectives</h3> To evaluate the prevalence of psoriatic arthritis (PsA) in PsO patients and assess how a novel 16-item visual instrument (PsA-Disk) correlates with the disease and its clinical manifestations. <h3>Methods</h3> Data were prospectively collected from 8 dermatological/rheumatological centres across Italy. During their first dermatological visit, patients completed both PEST (Psoriasis Epidemiology Screening Tool) and PsA-disk questionnaires. Rheumatological visit was performed in order to confirm presence/absence of PsA. Clinimetric and disease activity variables were recorded. <h3>Results</h3> From a total of 239 PsO patients, 120 (50.2%) patients were diagnosed with PsA. More PsA-positive patients had nail PsO (54.2% vs. 42%, p=0.05) and a PEST score ≥3 vs. PsA-negative patients (77.5% vs. 37.8%, p&lt;0.001). PsA-positive patients presented with significantly higher ESR (21.9±17.1 vs. 15.9±10.2 mm/h, p=0.041), NAPSI-feet (10.2±9.7 vs. 3.9±7.8, p=0.002), NAPSI-(hands+feet; 9.3±6.8 vs. 4.6±7.9, p=0.007), and PsA-Disk scores (73.9±32.1 vs. 58.1±39.8, p&lt;0.001) vs. PsA-negative patients. PsA-patients with axial involvement had higher PsA-Disk scores (86.7 vs. 72.5, p=0.088) as well as patients with knee arthritis (98.4 vs. 71.5, p=0.006). PsA-Disk scores were also positively correlated with number of swollen (r=0.2, p&lt;0.05) and tender joints (r=0.24, p=0.021), patient- (r=0.4, p&lt;0.001) and physician-pain-VAS (r=0.33, p&lt;0.001), PGA-VAS (r=0.23, p=0.025), physician-HAQ (r=0.38, p=0.011), DAS-44 (r=0.25, p=0.023) and DAPSA scores (r=0.31, p=0.005) (figure 1A). Examples of the powerful visual use of this instrument can be seen in figure 1B. <h3>Conclusions</h3> PsA-Disk is a novel instrument helping both dermatologist and rheumatologist in the rapid assessment PsA, facilitating in the timely therapeutic management of these patients. <h3>Disclosure of Interest</h3> None declared
SAT0151 Cardiorespiratory fitness in patients with rheumatoid arthritis
Authors: M. H. Liff, M. Hoff, T. Fremo, U. Wisløff, R. Thomas, V. Videm
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Mortality rates are higher in RA patients compared to the general population, mostly due to cardiovascular disease (CVD). Cardiorespiratory fitness (CRF) is inversely associated with CVD, but little is known about CRF levels in RA patients. <h3>Objectives</h3> To study the association between CRF in RA patients (measured as VO<sub>2</sub>peak), and CVD risk factors and RA-specific clinical variables. <h3>Methods</h3> 93 patients were recruited from a hospital rheumatology outpatient clinic. VO<sub>2</sub>peak was measured by ergospirometry during a treadmill test. Tender and swollen joint count, height, weight, waist circumference, resting heart rate, blood pressure and hsCRP were measured. RA characteristics and information on comorbidity were recorded from an interview and from medical records. Based on a previously published index weighting frequency, intensity and duration of self-reported physical activity (PA) (1), patients were categorized into four different PA categories (table 1). VO<sub>2</sub>peak was analyzed using multivariate linear regression, adjusting for age and gender. All participants signed an informed consent and the regional ethics committee approved the study. <h3>Results</h3> <h3>Conclusions</h3> We observed a strong association between common CVD risk factors (inactivity, high BMI, high resting heart rate) and lower CRF in RA patients, similar to published findings from the general population. Patients in the "Active" and "Very active" PA categories showed significantly higher VO<sub>2</sub>peak, whereas RA-specific variables such as seropositivity, disease activity, disease duration and medications had no impact on VO<sub>2</sub>peak. We cannot exclude a selection bias because more fit patients could be more likely to participate in the study. <h3>Reference</h3> [1]Nes BM, Janszky I, Vatten LJ, Nilsen TI, Aspenes ST, Wisloff U. Estimating VO<sub>2</sub>peak from a nonexercise prediction model: the HUNT Study, Norway. Med Sci Sports Exerc2011;43(11):2024–30. <h3>Acknowledgements:</h3> The VO<sub>2</sub>peak testing was performed at the core facility NeXt Move, NTNU – Norwegian University of Science and Technology. <h3>Disclosure of Interest:</h3> None declared
The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug
Authors: Young Seok Cho, Seung Woo Chung, Ha Rin Kim, Tae Hyung Won, Jeong Uk Choi, In-San Kim, Sang Yoon Kim, Youngro Byun
Journal: Journal of Controlled Release (2019)
Comment on Desai et al. Health Care Utilization and Burden of Diabetic Ketoacidosis in the U.S. Over the Past Decade: A Nationwide Analysis. Diabetes Care 2018;41:1631–1638
Authors: Rodolfo J. Galindo, Cesar Zambrano, Priyathama Vellanki
Journal: Diabetes Care (2019)

We read with great interest the outstanding study by Desai et al. (1) in the recent issue of Diabetes Care.The authors aimed to determine the incidence and costs of hospitalizations for diabetes ketoacidosis (DKA) in the U.S. The authors searched the National Inpatient Sample (NIS) database for all DKA admissions during 2003-2014.Consistent with recent Centers for Disease Control and Prevention reports (2), the study confirmed a decrease in hospital mortality but a significant increase in the number of hospitalizations for DKA.Notably, they reported a significant increase (56%) in the "inflation-adjusted hospital charges" for DKA admissions, from $18,987 in 2003 to $26,566 in 2014 (P , 0.001).Thus, the inflation-adjusted "national bill" for DKA hospitalization was estimated to be $5.1 billion in 2014.It is noteworthy that the authors used the terms "charges" and "costs" interchangeably in the abstract and article.Extensive evidence supports that hospital charges should not be used as a direct estimate of the cost of hospital care (3-5).For instance, hospital charges, defined as the amount billed by hospitals for the services rendered, do not actually reflect hospital costs, defined as how much the hospital service actually costs or was paid to the hospital.Hospital costs are the actual expenses incurred by hospitals in rendering the service, including wages, supplies, and utility
SAT0038 Membrane-associated ampd2, a novel regulator in shifting the balance between extracellular atp and adenosine?
Authors: L. Ehlers, A. Kuppe, A. Damerau, Y. Chen, F. Buttgereit, T. Gaber
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Extracellular ATP and adenosine are potent immunomodulatory molecules that accumulate in states of inflammation. ATP/ADP are released from damaged or stressed cells and sequentially catabolized to AMP which is then catabolized to adenosine by the action of the ectonucleotidases CD39 and CD73, which drives a shift from an ATP-driven proinflammatory environment to an anti-inflammatory milieu induced by adenosine. Intracellularly, AMPD2 which encodes one of three known AMP deaminase homologs executes AMP deamination to IMP thereby reducing the formation of adenosine. Here, we postulate that this mode of action is also present on the cell surface of immune cells, which may lead to an increased state of inflammation such as found in chronic inflammatory diseases. <h3>Objectives</h3> Therefore, we analysed surface AMPD2 expression and its modulation on distinct human cell lines and primary human immune cells. <h3>Methods</h3> To this end, surface AMPD2 expression was evaluated on cell lines (THP1, Jurkat, HMEC1, and HEK293), human PBMCs and isolated monocytes by flow cytometry. Moreover, co-expression of surface AMPD2, CD73 and CD39 has been analysed on PBMCs and isolated monocytes. Association of surface AMPD2 and cell death was visualised using annexin V and 7-AAD staining and examined by flow cytometry. In addition, expression of AMPD2 was analysed by immunoblot of precipitated AMPD2 from membrane fractions and by mass spectrometry after precipitation from membrane fractions and from biotinylated surface-molecules using the surface AMPD2 positive cell line HEK293. <h3>Results</h3> Here, we demonstrate that (i) surface AMPD2 is present on T cells and monocytes in PBMCs from healthy donors, (ii) that LPS enhances surface expression of AMPD2 in PBMCs on both cell populations after 24 hour, (iii) that LPS also enhances surface expression of AMPD2 in isolated monocytes, (iv) that surface AMPD2 does not correlate to the expression of the ectonucleotidases CD39 and CD73 and (v) that all cell lines analysed are capable of expressing surface AMPD2. Using HEK293, surface AMPD2 expression was reduced after Golgi transport inhibition. AMPD2 surface expression was not accompanied by enhanced cell death. Expression of AMPD2 could be confirmed in membrane fractions of HEK293 using immunoblot of precipitated AMPD2 and mass spectrometry, respectively. <h3>Conclusions</h3> Here, we demonstrate for the first-time surface expression of AMPD2 on immune cells enabling these cells to extracellularly convert AMP into IMP constituting a shunt-like mechanism to control the levels of adenosine and extracellular ATP formed from adenine nucleotides thereby controlling immunomodulation. <h3>Disclosure of Interest</h3> None declared
Trends in Opioid Prescribing and Dispensing by Veterinarians in Pennsylvania
Authors: Dana L. Clarke, Kenneth J. Drobatz, Chloe Korzekwa, Lewis S. Nelson, Jeanmarie Perrone
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Veterinarians are a subset of opioid prescribers. <h3>Objective</h3> To assess the quantity and trends in prescribing and dispensing of several different opioids in the past 11 years in a large veterinary hospital in Philadelphia, Pennsylvania. <h3>Design, Setting, and Participants</h3> This cross-sectional study inventoried all opioid tablets and/or patches dispensed or prescribed by veterinarians practicing in a multispecialty academic veterinary teaching hospital in Philadelphia for small animals and species, such as rabbits, birds, and reptiles, from January 1, 2007, through December 31, 2017. Prescribing data were obtained from all veterinarians who wrote a prescription for opioids by reviewing detailed pharmacy records of controlled substances for the study period. Data included all opioids dispensed, or prescribed to animals (patients) undergoing evaluation at the center or being followed up as outpatients by the veterinarians in the hospital. Statewide veterinarian prescribing data were used for comparison. Data were analyzed from December 24, 2017, through May 15, 2018. <h3>Main Outcomes and Measures</h3> The trend in administration and prescribing of 4 specific opioid analgesics (codeine sulfate, hydrocodone bitartrate, and tramadol hydrochloride tablets as well as fentanyl citrate patch) during the 11-year study period. The individual opioids were converted to morphine milligram equivalents (MME) for comparison. <h3>Results</h3> The study included 134 veterinarians (70.9% women) with 366 468 patient visits. During the study period, the hospital veterinarians prescribed 1 051 836 tablets of tramadol, 97 547 tablets of hydrocodone, 38 939 tablets of codeine, and 3153 fentanyl patches to dogs (73.0%), cats (22.5%), and exotic animals (4.5%). Overall, MME use increased 41.2%, whereas visits increased by 12.8%. The comparison data for Pennsylvania revealed a predominance of hydrocodone use (688 340 tablets prescribed), although data were not available for comparison with tramadol because it is a Schedule IV drug. <h3>Conclusions and Relevance</h3> Results of this study suggest that the large, increasing volume of opioids prescribed at 1 veterinary teaching hospital highlights concerns parallel to those about excessive opioid prescribing in humans. The extent to which these data may represent similar volumes of prescriptions from the general veterinary practices and hospitals across the United States is suggested by the accompanying Pennsylvania state data. These findings highlight an opportunity to assess the risk of veterinarian opioid prescriptions to safeguard public health.